1. Japan Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
Nippon Soda Co., Ltd.

Nippon Soda Co., Ltd.

TTSE:4041
3,605.00
JPY
-10.00
(-0.28%)
187.34BMarket Cap
Nov 12Next Earn
Nippon Soda Co., Ltd.
TSE:4041
(Tokyo Stock Exchange)

Recent

price

3,605.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
2,025.38
1,990.61
2,096.9
2,312.07
2,434.93
2,313.31
2,101.66
2,339.64
2,413.32
2,401.11
2,415.64
2,732.35
3,099.49
2,776.92
2,818
2,801.42
- -
Revenue per Share
91.18
115.77
87.16
95.89
179.99
232.01
143.52
105.66
96.13
112.13
127.57
227.19
299.38
298.72
272.56
336.54
- -
Basic EPS, GAAP
103.08
78.72
6.36
45.45
55.34
53.48
546.59
60.14
40.41
22.86
14.09
45.8
53.83
-102.33
63.24
128.46
- -
Free Cash Flow per Basic Share
20.2
14.94
14.94
14.94
19.93
37.12
32.54
29.98
29.97
30.03
45.69
62.77
107.24
134.95
119.8
150.91
- -
Dividend per Share
1,329.52
1,415.63
1,552.87
1,681
1,987.13
2,072.26
2,242.49
2,349.25
2,349.01
2,367.04
2,582.43
2,798.4
3,034.91
3,414.75
3,391.1
3,820.38
- -
Book Value per Share
1,266.91
1,346.34
1,499.06
1,634.49
1,946.08
2,038.86
2,216.28
2,326.18
2,253.31
2,285.27
2,484.62
2,709.23
2,963.3
3,347.45
3,340.94
3,783.11
- -
Tangible Book Value per Share
61
61
61
61
61
62
61
60
60
60
58
56
56
56
55
54
54
Basic Weighted Avg Shares
123,238
121,118
127,581
140,649
148,062
142,711
128,647
141,230
145,663
144,739
139,363
152,536
172,811
154,429
155,199
152,091
- -
Sales/Revenue/Turnover
3.84
3.89
3.21
4.55
4.92
5.2
4.17
4.53
5.43
5.62
7.16
7.82
9.78
8.98
10.35
9.84
- -
Operating Margin (%)
6,332
6,400
6,106
6,714
6,670
6,476
6,631
6,766
7,201
7,814
7,687
8,607
9,108
7,872
7,862
8,178
- -
Depreciation Expense
5,548
7,044
5,303
5,833
10,945
14,313
8,785
6,378
5,802
6,759
7,360
12,683
16,692
16,612
15,011
18,271
- -
Net Income, GAAP
19.04
21.95
25.92
26.12
14.39
23.77
15.15
23.13
28.88
13.24
19.23
25.43
30.12
21.72
25.35
25.89
- -
Effective Tax Rate (%)
4.5
5.82
4.16
4.15
7.39
10.03
6.83
4.52
3.98
4.67
5.28
8.31
9.66
10.76
9.67
12.01
- -
Profit Margin (%)
16,321
16,215
18,731
20,141
26,387
25,971
46,807
53,675
48,777
53,845
55,789
51,727
64,004
73,895
67,733
76,550
- -
Working Capital
13,692
13,898
18,386
18,027
17,405
14,019
7,569
12,846
10,604
13,514
21,535
16,414
16,943
25,118
23,325
33,653
- -
LT Debt
85,723
91,671
100,243
108,223
127,178
131,488
138,066
144,800
144,915
144,437
149,201
158,296
170,957
189,472
188,100
206,091
- -
Total Equity
1.3
2.66
2.07
3.02
3.68
3.14
2.52
2.76
3.21
4.08
4.45
4.58
5.8
4.86
5
4.42
- -
Return on Invested Capital (%)
4.37
5.3
3.84
3.9
6.67
8.12
5.02
3.62
3.29
3.93
4.11
6.54
8.32
7.58
6.38
7.53
- -
Return on Capital (%)
6.92
8.43
5.87
5.93
9.81
11.46
6.65
4.6
4.09
4.78
5.13
8.41
10.27
9.3
8.01
9.33
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
24,401
18,617
- -
LT Borrowings
27,450
33,653
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
187,222
187,337
189,488

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
118,184
125,328
- -
Cash, Cash Equivalents & STI
22,675
24,626
- -
Accounts Receivable, Net
29,116
39,972
- -
Inventories
57,813
52,962
- -
Total Current Liabilities
50,463
48,778
- -
Payables & Accruals
- -
- -
- -
ST Debt
24,401
18,617
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.67%
6.75%
9.56%
Free Cash Flow
58.9%
-23.75%
100.23%
Net Income, GAAP
6.59%
23.11%
21.72%
Sales/Revenue/Turnover
0.93%
2.12%
-2%
Total Cash Common Dividend
16.46%
28.23%
24.17%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
155,199
2026
- -
- -
- -
- -
152,091
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
272.56
2026
- -
- -
- -
- -
336.54
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
119.8
2026
- -
- -
- -
- -
150.91
2027
- -
- -
- -
- -
- -
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
AARTI Industries Ltd (NSE:AARTIIND)
Aether Industries Ltd. (NSE:AETHER)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
Nippon Soda Co., Ltd. manufactures and markets a diverse portfolio of chemical products, encompassing agri-business offerings such as fungicides including thiophanate-methyl, insecticides, acaricides, herbicides, and industrial fungicides; pharmaceuticals comprising active pharmaceutical ingredients, intermediates, and excipients like hydroxypropyl cellulose (NISSO HPC); specialty chemicals leveraging proprietary technologies for high-value applications in electronics and industrial materials; eco chemicals supporting environmental protection, safety, and health; and chlor-alkali products including caustic soda and related basic industrial chemicals. The company operates through segments including chemicals, agro products, trading, transportation and warehousing, construction, and others, serving global markets with an overseas sales ratio of approximately 50% as of fiscal year 2025; it maintains key production facilities such as the Nihongi Plant in Niigata Prefecture, Takaoka Plant in Toyama Prefecture, and Chiba Plant. Founded in 1920 and headquartered at JP Tower in Chiyoda-ku, Tokyo, Japan, Nippon Soda focuses on agriculture, healthcare, environment, and ICT sectors to create societal value through chemistry under its long-term vision "Brilliant Through Chemistry 2030." In recent developments, the company formed a capital and business alliance with Kyulux Inc. in October 2024 to develop mass production systems for thermally activated delayed fluorescence (TADF) materials for OLED displays, building on their joint development agreement since 2020; additionally, in August 2025, it entered a joint research and development agreement with KAICO Ltd. for veterinary pharmaceuticals.